

Product datasheet for **TL313558V**

HIP55 (DBNL) Human shRNA Lentiviral Particle (Locus ID 28988)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	HIP55 (DBNL) Human shRNA Lentiviral Particle (Locus ID 28988)
Locus ID:	28988
Synonyms:	ABP1; HIP-55; HIP55; SH3P7
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	DBNL - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001014436 , NM_001122956 , NM_001284313 , NM_001284315 , NM_014063 , NM_014063.1 , NM_014063.2 , NM_014063.3 , NM_014063.4 , NM_014063.5 , NM_014063.6 , NM_001014436.1 , NM_001014436.2 , NM_001122956.1 , NM_001284313.1 , NM_001284315.1 , BC011677 , BC023589 , BC031687 , NM_001362723 , NM_014063.7 , NM_001122956.2 , NM_001284313.2 , NM_001014436.3
UniProt ID:	Q9UJU6
Summary:	Adapter protein that binds F-actin and DNM1, and thereby plays a role in receptor-mediated endocytosis. Plays a role in the reorganization of the actin cytoskeleton, formation of cell projections, such as neurites, in neuron morphogenesis and synapse formation via its interaction with WASL and COBL. Does not bind G-actin and promote actin polymerization by itself. Required for the formation of organized podosome rosettes (By similarity). May act as a common effector of antigen receptor-signaling pathways in leukocytes. Acts as a key component of the immunological synapse that regulates T-cell activation by bridging TCRs and the actin cytoskeleton to gene activation and endocytic processes.[UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online >](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).